Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
| Revenue (Most Recent Fiscal Year) | $4.07B |
| Net Income (Most Recent Fiscal Year) | $560.12M |
| PE Ratio (Current Year Earnings Estimate) | 70.06 |
| PE Ratio (Trailing 12 Months) | 40.27 |
| PEG Ratio (Long Term Growth Estimate) | 7.84 |
| Price to Sales Ratio (Trailing 12 Months) | 1.85 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.10 |
| Pre-Tax Margin (Trailing 12 Months) | -12.51% |
| Net Margin (Trailing 12 Months) | -9.91% |
| Return on Equity (Trailing 12 Months) | 5.02% |
| Return on Assets (Trailing 12 Months) | 1.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.17 |
| Inventory Turnover (Trailing 12 Months) | 0.91 |
| Book Value per Share (Most Recent Fiscal Quarter) | $61.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-9.07 |
| Earnings per Share (Most Recent Fiscal Year) | $17.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.73 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.66M |
| Free Float | 58.05M |
| Market Capitalization | $7.55B |
| Average Volume (Last 20 Days) | 0.90M |
| Beta (Past 60 Months) | 0.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |